In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Sarepta Therapeutics (SRPT). The company’s shares opened today at $126.11.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 10.8% and a 39.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Aclaris Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $214.17, which is a 69.8% upside from current levels. In a report released yesterday, Cowen & Co. also assigned a Buy rating to the stock with a $213 price target.
See today’s analyst top recommended stocks >>
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $276 million. In comparison, last year the company had a GAAP net loss of $109 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 10,000 shares for a total of $1,200,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
